Patents by Inventor J. Gordon Foulkes

J. Gordon Foulkes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of treating a patient afflicted with non-alcoholic steatohepatitis (NASH)
    Patent number: 11865113
    Abstract: Pharmaceutical carriers which provide an environment of physical and chemical stability comprising a therapeutically effective amount of an active pharmaceutical ingredient (API) compound of structure I, one or more antioxidants, one or more chelators and a vehicle base comprising water and one or more pharmaceutically acceptable non-aqueous solvents, one or more absorption enhancers, one or more gelling agents and one or more pH buffering agents are described.
    Type: Grant
    Filed: June 6, 2017
    Date of Patent: January 9, 2024
    Assignee: LIPIDIO PHARMACEUTICALS INC.
    Inventors: Nigel R. A. Beeley, J. Gordon Foulkes, Kieran George Mooney, Charles Rodney Greenaway Evans, Keith Arthur Johnson, Howard G. Welgus, Celia P. Jenkinson
  • FORMULATIONS FOR SUBSTITUTED 3-PYRROLIDINES, COMPOSITIONS CONTAINING, AND USES OF, SAME
    Publication number: 20200306248
    Abstract: Pharmaceutical carriers which provide an environment of physical and chemical stability comprising a therapeutically effective amount of an active pharmaceutical ingredient (API) compound of structure I, one or more antioxidants, one or more chelators and a vehicle base comprising water and one or more pharmaceutically acceptable non-aqueous solvents, one or more absorption enhancers, one or more gelling agents and one or more pH buffering agents are described.
    Type: Application
    Filed: June 6, 2017
    Publication date: October 1, 2020
    Applicant: GDD Therapeutics, LLC
    Inventors: Nigel R.A. Beeley, J. Gordon Foulkes, Kieran George Mooney, Charles Rodney Greenaway Evans, Keith Arthur Johnson, Howard G. Welgus, Celia P. Jenkinson, James R. Hauske
  • METHOD OF TREATING KELOIDS OR HYPERTROPHIC SCARS USING ANTISENSE COMPOUNDS TARGETING CONNECTIVE TISSUE GROWTH FACTOR (CTGF)
    Publication number: 20200190521
    Abstract: This invention provides methods of preventing formation of, or treating, fibrotic lesions, including skin scars such as keloids and hypertrophic scars which comprise administering to the subject by one or more injection a compound which comprises a modified oligonucleotide, such as a modified antisense oligonucleotide, siRNA, or oligodeoxyribonucleotide, which inhibits expression of protein involved in fibrosis. Dosing of the antisense using an intradermal threading technique is also described.
    Type: Application
    Filed: September 20, 2019
    Publication date: June 18, 2020
    Applicant: Excaliard Pharmaceuticals, Inc.
    Inventors: Nicholas M. Dean, Lincoln Krochmal, Gregory Hardee, J. Gordon Foulkes, Niall O'Donnell, Leroy Young, Mark Jewell
  • ANTISENSE OLIGONUCLEOTIDES DIRECTED AGAINST CONNECTIVE TISSUE GROWTH FACTOR AND USES THEREOF
    Publication number: 20190323013
    Abstract: This invention provides compounds which comprise modified oligonucleotides capable of inhibitory expression of connective tissue factor and composition containing same as well as methods of treating hyperprolific disorders and fibrotic diseases, and of reducing scarring resulting from wound healing using such compounds.
    Type: Application
    Filed: November 29, 2018
    Publication date: October 24, 2019
    Inventors: Nicholas M. Dean, J. Gordon Foulkes, Niall O'Donnell, C. Frank Bennett, Susan M. Freier
  • 12H-BENZO[b]XANTHEN-12-ONES, COMPOSITIONS CONTAINING, AND USES OF, SAME
    Publication number: 20180185325
    Abstract: The present invention provides compounds of the following structure, methods of using such compounds, and pharmaceutical compositions containing such compounds. In addition, this invention provides methods for the treatment and/or prevention of disease states mediated by Aryl Hydrocarbon receptor pathways.
    Type: Application
    Filed: June 8, 2016
    Publication date: July 5, 2018
    Applicant: Thesan Pharmaceuticals, Inc.
    Inventors: Nigel Robert Arnold Beeley, Howard Glenn Welgus, Jay Edward Birnbaum, J. Gordon Foulkes, Celia Patricia Jenkinson, Jean Hilaire Saurat
  • 12H-BENZO[b]XANTHEN-12-ONES, COMPOSITIONS CONTAINING, AND USES OF, SAME
    Publication number: 20180179174
    Abstract: The present invention provides compounds of the following structure, methods of using such compounds, and pharmaceutical compositions containing such compounds. In addition, this invention provides methods for the treatment and/or prevention of disease states mediated by Aryl Hydrocarbon receptor pathways.
    Type: Application
    Filed: June 6, 2016
    Publication date: June 28, 2018
    Applicant: Thesan Pharmaceuticals, Inc.
    Inventors: Nigel Robert Arnold Beeley, Howard Glenn Welgus, Jay Edward Birnbaum, J. Gordon Foulkes, Celia Patricia Jenkinson, Jean Hilaire Saurat
  • BETA-NAPHTHOISOFLAVONES, COMPOSITIONS CONTAINING, AND USES OF, SAME
    Publication number: 20180118707
    Abstract: The present invention provides compounds of the following structure, methods of using such compounds, and pharmaceutical compositions containing such compounds. In addition, this invention provides methods for the treatment and/or prevention of disease states mediated by Aryl Hydrocarbon receptor pathways.
    Type: Application
    Filed: June 7, 2016
    Publication date: May 3, 2018
    Applicant: Thesan Pharmaceuticals, Inc.
    Inventors: Nigel Robert Arnold Beeley, Howard Glenn Welgus, Jay Edward Birnbaum, J. Gordon Foulkes, Celia Patricia Jenkinson, Jean Hilaire Saurat
  • ANTISENSE OLIGONUCLEOTIDES DIRECTED AGAINST CONNECTIVE TISSUE GROWTH FACTOR AND USES THEREOF
    Publication number: 20170335329
    Abstract: This invention provides compounds which comprise modified oligonucleotides capable of inhibitory expression of connective tissue factor and composition containing same as well as methods of treating hyperprolific disorders and fibrotic diseases, and of reducing scarring resulting from wound healing using such compounds.
    Type: Application
    Filed: May 23, 2017
    Publication date: November 23, 2017
    Inventors: Nicholas M. Dean, J. Gordon Foulkes, Niall O'Donnell, C. Frank Bennett, Susan M. Freier
  • Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
    Patent number: 9688987
    Abstract: This invention provides compounds which comprise modified oligonucleotides capable of inhibitory expression of connective tissue factor and composition containing same as well as methods of treating hyperprolific disorders and fibrotic diseases, and of reducing scarring resulting from wound healing using such compounds.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: June 27, 2017
    Assignees: Excaliard Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc.
    Inventors: Nicholas M. Dean, J. Gordon Foulkes, Niall O'Donnell, C. Frank Bennett, Susan M. Freier
  • METHOD OF TREATING KELOIDS OR HYPERTROPHIC SCARS USING ANTISENSE COMPOUNDS TARGETING CONNECTIVE TISSUE GROWTH FACTOR (CTGF)
    Publication number: 20170022501
    Abstract: This invention provides methods of preventing formation of, or treating, fibrotic lesions, including skin scars such as keloids and hypertrophic scars which comprise administering to the subject by one or more injection a compound which comprises a modified oligonucleotide, such as a modified antisense oligonucleotide, siRNA, or oligodeoxyribonucleotide, which inhibits expression of protein involved in fibrosis. Dosing of the antisense using an intradermal threading technique is also described.
    Type: Application
    Filed: September 25, 2015
    Publication date: January 26, 2017
    Applicant: EXCALIARD PHARMACEUTICALS, INC.
    Inventors: Nicholas M. Dean, Lincoln Krochmal, Gregory Hardee, J. Gordon Foulkes, Niall O'Donnell, Leroy Young, Mark Jewell
  • ANTISENSE OLIGONUCLEOTIDES DIRECTED AGAINST CONNECTIVE TISSUE GROWTH FACTOR AND USES THEREOF
    Publication number: 20150376623
    Abstract: This invention provides compounds which comprise modified oligonucleotides capable of inhibitory expression of connective tissue factor and composition containing same as well as methods of treating hyperprolific disorders and fibrotic diseases, and of reducing scarring resulting from wound healing using such compounds.
    Type: Application
    Filed: June 29, 2015
    Publication date: December 31, 2015
    Applicants: EXCALIARD PHARMACEUTICALS, INC., ISIS PHARMACEUTICALS, INC.
    Inventors: Nicholas M. Dean, J. Gordon Foulkes, Niall O'Donnell, C. Frank Bennett, Susan M. Freier
  • Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (CTGF)
    Patent number: 9173894
    Abstract: This invention provides methods of preventing formation of, or treating, fibrotic lesions, including skin scars such as keloids and hypertrophic scars which comprise administering to the subject by one or more injection a compound which comprises a modified oligonucleotide, such as a modified antisense oligonucleotide, siRNA, or oligodeoxyribonucleotide, which inhibits expression of protein involved in fibrosis. Dosing of the antisense using an intradermal threading technique is also described.
    Type: Grant
    Filed: February 2, 2012
    Date of Patent: November 3, 2015
    Assignee: Excaliard Pharamaceuticals, Inc.
    Inventors: Nicholas M. Dean, Lincoln Krochmal, Gregory Hardee, J. Gordon Foulkes, Niall O'Donnell, Leroy Young, Mark Jewell
  • Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
    Patent number: 9096851
    Abstract: This invention provides compounds which comprise modified oligonucleotides capable of inhibitory expression of connective tissue factor and composition containing same as well as methods of treating hyperprolific disorders and fibrotic diseases, and of reducing scarring resulting from wound healing using such compounds.
    Type: Grant
    Filed: June 25, 2012
    Date of Patent: August 4, 2015
    Assignees: Excaliard Pharmaceuticals, Inc., Isis Pharmaceuticals, Inc.
    Inventors: Nicholas M. Dean, J. Gordon Foulkes, Niall O'Donnell, C. Frank Bennett, Susan M. Frier
  • Methods for inhibiting expression of connective tissue growth factor
    Patent number: 8772260
    Abstract: This invention provides compounds which comprise modified oligonucleotides capable of inhibitory expression of connective tissue factor and composition containing same as well as methods of treating hyperprolific disorders and fibrotic diseases, and of reducing scarring resulting from wound healing using such compounds.
    Type: Grant
    Filed: August 13, 2012
    Date of Patent: July 8, 2014
    Assignees: Isis Pharmaceuticals, Inc, Excaliard Pharmaceuticals, Inc
    Inventors: Nicholas M. Dean, J. Gordon Foulkes, Niall O'Donnell, C. Frank Bennett, Susan M. Frier
  • ANTISENSE OLIGONUCLEOTIDES DIRECTED AGAINST CONNECTIVE TISSUE GROWTH FACTOR AND USES THEREOF
    Publication number: 20130190380
    Abstract: This invention provides compounds which comprise modified oligonucleotides capable of inhibitory expression of connective tissue factor and composition containing same as well as methods of treating hyperprolific disorders and fibrotic diseases, and of reducing scarring resulting from wound healing using such compounds.
    Type: Application
    Filed: June 25, 2012
    Publication date: July 25, 2013
    Inventors: Nicholas M. Dean, J. Gordon Foulkes, Niall O'Donnell, C. Frank Bennett, Susan M. Frier
  • METHODS FOR INHIBITING EXPRESSION OF CONNECTIVE TISSUE GROWTH FACTOR
    Publication number: 20130190382
    Abstract: This invention provides compounds which comprise modified oligonucleotides capable of inhibitory expression of connective tissue factor and composition containing same as well as methods of treating hyperprolific disorders and fibrotic diseases, and of reducing scarring resulting from wound healing using such compounds.
    Type: Application
    Filed: August 13, 2012
    Publication date: July 25, 2013
    Inventors: Nicholas M. Dean, J. Gordon Foulkes, Niall O'Donnell, C. Frank Bennett, Susan M. Frier
  • METHOD OF TREATING KELOIDS OR HYPERTROPHIC SCARS USING ANTISENSE COMPOUNDS TARGETING CONNECTIVE TISSUE GROWTH FACTOR (CTGF)
    Publication number: 20120238937
    Abstract: This invention provides methods of preventing formation of, or treating, fibrotic lesions, including skin scars such as keloids and hypertrophic scars which comprise administering to the subject by one or more injection a compound which comprises a modified oligonucleotide, such as a modified antisense oligonucleotide, siRNA, or oligodeoxyribonucleotide, which inhibits expression of protein involved in fibrosis. Dosing of the antisense using an intradermal threading technique is also described.
    Type: Application
    Filed: February 2, 2012
    Publication date: September 20, 2012
    Inventors: Nicholas M. Dean, Lincoln Krochmal, Gregory Hardee, J. Gordon Foulkes, Niall O'Donnell, Leroy Young, Mark Jewell
  • Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
    Patent number: 8252762
    Abstract: This invention provides compounds which comprise modified oligonucleotides capable of inhibitory expression of connective tissue factor and composition containing same as well as methods of treating hyperprolific disorders and fibrotic diseases, and of reducing scarring resulting from wound healing using such compounds.
    Type: Grant
    Filed: August 25, 2009
    Date of Patent: August 28, 2012
    Assignees: Excaliard Pharmaceuticals, Inc., Isis Pharmaceuticals, Inc.
    Inventors: Nicholas M. Dean, J. Gordon Foulkes, Niall O'Donnell, C. Frank Bennett, Susan M. Frier
  • MODULATION OF SMAD3 EXPRESSION
    Publication number: 20110213011
    Abstract: Provided are compounds capable of inhibiting SMAD3 and compositions containing same as well as methods using such compounds for treating fibrosis and scarring.
    Type: Application
    Filed: February 25, 2011
    Publication date: September 1, 2011
    Inventors: Nicholas M. Dean, J. Gordon Foulkes, Susan M. Freier, C. Frank Bennett, William A. Gaarde
  • MODULATION OF TRANSFORMING GROWTH FACTOR-BETA 1 EXPRESSION
    Publication number: 20110172296
    Abstract: Provided are compounds capable of inhibiting expression of TGF-beta 1 and compositions containing same as well as methods using such compounds for treating fibrotic diseases including the reduction of scarring resulting from wound healing.
    Type: Application
    Filed: January 12, 2011
    Publication date: July 14, 2011
    Inventors: C. Frank Bennett, Susan M. Freier, Nicholas M. Dean, J. Gordon Foulkes, William A. Gaarde